Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients

Journal of Investigative Dermatology

Volumn 125, Issue 6, 2005, Pages 1273-1278

  Bouaziz, Jean David ^b   Ortonne, Nicolas ^b   Giustiniani, Jérôme ^b   Schiavon, Valérie ^b   Huet, Delphine ^b   Bagot, Martine ^b   Bensussan, Armand ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b NONE

Author keywords

Cutaneous lymphoma; Lymphocyte; Natural killer; Sezary syndrome

Indexed keywords

ALEMTUZUMAB; CHROMIUM 51; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AZ158; UNCLASSIFIED DRUG; LEUKOCYTE ANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER T CELL; PRIORITY JOURNAL; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; CYTOTOXICITY; DISEASE PREDISPOSITION; GENETICS; IMMUNOLOGY; NATURAL KILLER CELL; TUMOR CELL LINE;

ANTIGENS, CD; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE SUSCEPTIBILITY; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; SEZARY SYNDROME;

EID: 33644817053     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23914.x     Document Type: Article

References (39)

1. Bagot M, Echchakir H, Mami-Chouaib F, et al: Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 91:4331-4341, 1998
2. Bagot M, Martinvalet D, Echchakir H, Chabanette-Schirm F, Boumsell L, Bensussan A: Functional inhibitory receptors expressed by a cutaneous T cell lymphoma-specific cytolytic clonal T cell population. J Invest Dermatol 115:994-999, 2000
3. Bagot M, Moretta A, Sivori S, et al: CD4+cutaneous T cell lymphoma cells express the p140/Killer cell immunoglobulin-like receptor. Blood 97:1388-1391, 2001
4. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J: Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol 22:1-6, 1992
5. Biassoni R, Cantoni C, Marras D, et al: Human natural killer cell receptors: Insights into their molecular function and structure. J Cell Mol Med 7:376-387, 2003
6. Bix M, Liao N-S, Zijlstra M, Loring J, Jaenisch R, Raulet D: Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349:329-331, 1991
7. Boumsell L, Bernard A, Reinherz EL, et al: Surface antigens on malignant Sezary and T-CLL cells correspond to those of mature T cells. Blood 57:526-530, 1981
8. Cerwenka A, Baron JL, Lanier LL: Ectopic expression of retinoic acid early inducible-1-gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98: 11521-11526, 2001
9. Diefenbach A, Jensen ER, Jamieson AM, Raulet D: Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature 413:165-171, 2001
10. Echchakir H, Bagot M, Dorothée G, et al: Cutaneous T cell lymphoma-reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a Fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 115 :74-80, 2000
11. Edelson RL: Cutaneous T cell lymphoma: Mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 2:89-106, 1980
12. 2m-bone marrow in chimeric mice. Proc Natl Acad Sci USA 88:10332-10336, 1991
13. Jensen JR, Kaltoft K, Bisballe S, Thestrup-Pedersen K: Natural and concanavalin A-induced cytotoxic activity towards continuously growing B lymphocytes derived from patients with cutaneous T-cell lymphoma. Arch Dermatol Res 279:12-15, 1986
14. Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675-678, 1986
15. Kennedy GA, Seymour JF, Wolf M, et al: Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 71:250-256, 2003
16. Lanier LL: NK cell recognition. Annu Rev Immunol 23:225-274, 2005
17. Laroche L, Kaiserlian D: Decreased natural-killer-cell activity in cutaneous T-cell lymphomas. N Engl J Med 308:101-102, 1983
18. Le Bouteiller P, Barakonyi A, Giustiniani J, et al: Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci USA 99:16963-16968, 2002
19. Maiza H, Leca G, Mansur I-G, Schiavon V, Boumsell L, Bensussan A: A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med 178:1121-1126, 1993
20. Marolleau JP, Baccard M, Flageul B, et al: High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 131:574-579, 1995
21. Moretta A, Biassoni R, Bottino C, et al: Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 155:105-117, 1997
22. Oshimi K, Oshimi Y, Yamada O, Mizoguchi H: Lysis of lymphoma cells by autologous and allogeneic natural killer cells. Blood 65:638-643, 1985
23. Palucka KA, Reizenstein P, Ost A, Porwit-MacDonald A: Blocking of MHC class I antigens on leukemic B-cells enhances their conjugate formation with cytotoxic lymphocytes and their susceptibility to lysis. Leuk Lymphoma 28:573-581, 1998
24. Parolini S, Cantoni C, Castriconi R, et al: The AZ158 mAb specifically reacts with p70 and p140 inhibitory NK receptors for HLA-B and HLA-A alleles. In: Mason D, Andre P, Bensussan A, et al: (eds). Leucocyte Typing VII. Oxford: Oxford University Press, 2002; p 415-417
25. Pende D, Biassoni R, Cantoni C, et al: The natural killer cell receptor specific for HLA-A allotypes: A novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 184: 505-518, 1996
26. Poszepczynska E, Bagot M, Echchakir H, et al: Functional characterization of an IL-7-dependent CD4(+)CD8alphaalpha(+) Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood 96: 1056-1063, 2000
27. Poszepczynska-Guigne E, Schiavon V, D'Incan M, et al: CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: Relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol 122:820-823, 2004
28. Rieger K, Von Grunhagen U, Fietz T, Thiel E, Knauf W: Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia-change of regimen needed? Leuk Lymphoma 45:345-349, 2004
29. Rook AH, Kubin M, Cassin M, et al: IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 154:1491-1498, 1995
30. Tajima K, Matsumoto N, Ohmori K, et al: Augmentation of NK cell-mediated cytotoxicity to tumor cells by inhibitory NK cell receptor blockers. Int Immunol 16:385-393, 2004
31. Wahlberg BJ, Burholt DR, Kornblith P, et al: Measurement of NK activity by the microcytotoxicity assay (MCA): A new application for an old assay. J Immunol Methods 253:69-81, 2001
32. Waldmann H: A personal history of the CAMPATH-1H antibody. Med Oncol 19s:3-9, 2002
33. Wechsler J, Bagot M, Nikolova M, et al: Killer cell immunoglobulin-like receptor expression delineates in situ sezary syndrome lymphocytes. J Pathol 199:77-83, 2003
34. Wieselthier JS, Koh HK: Sezary syndrome: Diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 22:381-401, 1990
35. Wood NL, Kitces EN, Blaylock WK: Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. Arch Dermatol 126:907-913, 1990
36. Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner LJ, Rook A: Enhancement of the host immune responses in cutaneous T Cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 104:4142-4149, 2004
37. Wysocka M, Zaki MH, French LE, et al: Sezary syndrome patients demonstrate a defect in dendritic cell populations: Effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 100:3287-3294, 2002
38. Yoo EK, Cassin M, Lessin SR, Rook AH: Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol 45:208-216, 2001
39. Zaki MH, Wysocka M, Everetts SE, et al: Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: Basis for therapy of cutaneous T cell lymphoma. J Invest Dermatol 118:366-371, 2002